Oppenheimer Reiterates Outperform Rating on Xylem, Sets $150 Target
Oppenheimer reiterated its Outperform rating on Xylem and maintained a $150 price target. The target implies 46.3% upside from the Oct. 13 close of $102.54.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.